Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 CAD | +2.15% | +2.15% | +20.25% |
04-08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
03-14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.25% | 111M | |
+14.23% | 69.5B | |
+7.11% | 8.2B | |
-20.55% | 7.97B | |
-4.06% | 7.84B | |
+2.26% | 4.66B | |
+17.12% | 4.32B | |
+1.41% | 4.19B | |
-3.02% | 3.89B | |
+21.42% | 3.62B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Obtains Public Reimbursement for Vascepa in New Brunswick and with other Public Payors